Reviews
Antibiotic Use Linked to Poorer Overall Survival in HCC Treated With ICIs
Chen et alPeerJ

In a systematic review and meta-analysis of 12 retrospective cohort studies comprising 3,643 patients with hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitors (ICIs), antibiotic exposure (n = 761) was evaluated for its relationship with clinical and survival outcomes. Literature was retrieved across PubMed, Embase, and Cochrane Library databases up to August 7, 2026. Methodological quality of the included studies was appraised using the Newcastle-Ottawa Scale, and pooled hazard ratios (HRs) and odds ratios (ORs) were calculated after log-transformation using Stata 15 software.
Patients exposed to antibiotics experienced a shorter median overall survival (OS) of 12.2 months compared with 17.0 months in unexposed patients, with pooled analysis indicating that antibiotic use was significantly associated with poorer OS (HR = 1.29, 95% CI [1.17–1.41]). Sensitivity analyses confirmed the robustness of this OS finding.
For progression-free survival (PFS), the median duration was shorter among antibiotic-exposed patients compared to non-exposed patients (5.2 vs 7.5 months), and antibiotic use was significantly associated with poorer PFS (HR = 1.27, 95% CI [1.01–1.59]); however, this association was not robust upon sensitivity analysis and the authors noted it should be interpreted with caution. Analyses of objective response rate (ORR) and disease control rate (DCR) did not show statistically significant differences between the exposed and unexposed groups. Furthermore, visual inspection of funnel plots alongside Begg's and Egger's tests detected no significant publication bias.
Key Takeaways
- Antibiotic exposure in patients with hepatocellular carcinoma receiving immune checkpoint inhibitors was significantly associated with reduced overall survival (HR = 1.29, 95% CI [1.17–1.41]; median 12.2 vs 17.0 months), a finding confirmed to be robust in sensitivity analyses.
- While antibiotic use was associated with shorter progression-free survival (HR = 1.27, 95% CI [1.01–1.59]; median 5.2 vs 7.5 months), this association was not robust in sensitivity analyses, and no statistically significant differences were observed for objective response rate or disease control rate.
